Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Amoytop and Aligos Team Up in $109 Million Deal to Develop Novel Drugs for Liver Diseases

publication date: May 16, 2023

Xiamen Amoytop Biotech will collaborate with South San Francisco’s Aligos Therapeutics using Aligos’ platform to discover and develop oligonucleotides that treat liver diseases. Amoytop will have an option to acquire Greater China rights to any discovered drugs. Aligos will receive an upfront payment and research funding along with rest-of-world rights. It will be eligible to receive up to $109 million in development and sales milestone payments for licensed products as well as tiered royalties on net sales. Aligos develops targeted therapies for NASH and viral diseases, while Amoytop focuses on immune-related cytokine medicines. More details....

Stock Symbol: (NSDQ: ALGS)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital